Abstract
Although self monitoring of blood glucose is accepted to be effective in lowering Hb A1c levels in insulin-treated diabetic patients, any benefit in non-insulin-treated patients remains controversial. Observational studies cannot answer this question because of either patient self selection (individuals with healthier life styles chose to perform more SMBG) or physician self selection (patients in poorer control are asked to perform SMBG). Only randomized controlled trials (RCTs) can provide the answer. Of the 14 published bona fide RCTs, nine show no benefit in lowering Hb A1c levels. In four of the five positive ones, the SMBG group received more intensive education and/or treatment than the control group. In the one in which patients in both groups were followed similarly, over 500 patients were required to produce a statistically significant difference of 0.2% favoring SMBG, the clinical significance of which is debatable. Thus, there is scant evidence that very expensive SMBG in non-insulin-treated patients is effective in lowering Hb A1c levels. This lack of benefit argues for redirecting these resources into areas of diabetes care where strong evidence exists for improving diabetes outcomes.
Keywords: Self monitoring of blood glucose (SMBG), randomized controlled trials (RCTs), non-insulin-treated patients
Reviews on Recent Clinical Trials
Title: Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck
Volume: 5 Issue: 3
Author(s): Mayer B. Davidson
Affiliation:
Keywords: Self monitoring of blood glucose (SMBG), randomized controlled trials (RCTs), non-insulin-treated patients
Abstract: Although self monitoring of blood glucose is accepted to be effective in lowering Hb A1c levels in insulin-treated diabetic patients, any benefit in non-insulin-treated patients remains controversial. Observational studies cannot answer this question because of either patient self selection (individuals with healthier life styles chose to perform more SMBG) or physician self selection (patients in poorer control are asked to perform SMBG). Only randomized controlled trials (RCTs) can provide the answer. Of the 14 published bona fide RCTs, nine show no benefit in lowering Hb A1c levels. In four of the five positive ones, the SMBG group received more intensive education and/or treatment than the control group. In the one in which patients in both groups were followed similarly, over 500 patients were required to produce a statistically significant difference of 0.2% favoring SMBG, the clinical significance of which is debatable. Thus, there is scant evidence that very expensive SMBG in non-insulin-treated patients is effective in lowering Hb A1c levels. This lack of benefit argues for redirecting these resources into areas of diabetes care where strong evidence exists for improving diabetes outcomes.
Export Options
About this article
Cite this article as:
B. Davidson Mayer, Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck, Reviews on Recent Clinical Trials 2010; 5 (3) . https://dx.doi.org/10.2174/157488710792007248
DOI https://dx.doi.org/10.2174/157488710792007248 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Intracoronary Brachytherapy - Clinical State and Pathophysiological Considerations
Current Pharmaceutical Design Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Long-Term Metabolic Consequences in Patients with a History of Gestational Diabetes
Current Pharmaceutical Design The Podocyte: a Potential Therapeutic Target in Diabetic Nephropathy?
Current Pharmaceutical Design Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Stress and Aging
Current Genomics Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Design The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation
Current Topics in Medicinal Chemistry Exploring Modifications in Fetal Telomere Programming in Mothers Exposed to Multiple Risk Factors
Current Women`s Health Reviews Hitting the Jackpot Twice: Identifying and Patenting Gene Tests Related to Muscle Lipid Accumulation for Meat Quality in Animals and Type 2 Diabetes/Obesity in Humans
Recent Patents on DNA & Gene Sequences HDL as a Target for Glycemic Control
Current Drug Targets Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia
Current Pharmaceutical Design Current Progress in Molecular Responses to Acidosis in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups
Endocrine, Metabolic & Immune Disorders - Drug Targets